Long-term impact of type 2 diabetes onset on dementia incidence rate among New Zealanders with impaired glucose tolerance: A tapered-matched landmark analysis over 25 years.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: John Wiley & Sons, Ltd Country of Publication: United States NLM ID: 101231978 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1552-5279 (Electronic) Linking ISSN: 15525260 NLM ISO Abbreviation: Alzheimers Dement Subsets: MEDLINE
    • Publication Information:
      Publication: 2020- : Hoboken, NJ : John Wiley & Sons, Ltd.
      Original Publication: Orlando, FL : Elsevier, Inc.
    • Subject Terms:
      Diabetes Mellitus, Type 2*/epidemiology ; Dementia*/epidemiology ; Glucose Intolerance*/epidemiology; Humans ; New Zealand/epidemiology ; Incidence ; Male ; Female ; Aged ; Risk Factors ; Middle Aged ; Aged, 80 and over ; Australasian People
    • Abstract:
      Introduction: We aimed to investigate the association between the onset of type 2 diabetes (T2D) and dementia incidence rates (IR) in the population with impaired glucose tolerance (IGT) identified in primary care in New Zealand (NZ) over 25 years.
      Methods: Tapered matching and landmark analysis (accounting for immortal bias) were used to control for potential effects of known confounders. The association between T2D onset and 5- and 10-year IR of dementia was estimated by weighted Cox models.
      Results: The onset of T2D was significantly associated with the 10-year IR of dementia, especially in the socioeconomically deprived, those of non-NZ European ethnicity, those currently smoking, and patients with higher metabolic measures.
      Discussion: Our findings suggest that the onset of T2D is a significant risk factor for dementia in individuals with IGT. Dementia screening and structured diabetes prevention are vital in the population with IGT, particularly those from deprived or ethnic minority backgrounds.
      Highlights: Increased dementia incidence rate links with T2D onset in people with IGT. Significant incidence varied by ethnicity, socioeconomic status, and health factors. Results emphasize the diabetes manage and socioeconomic factors on dementia risk. Secondary analysis highlights the key role of vascular health in dementia prevention.
      (© 2024 The Author(s). Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association.)
    • References:
      Lancet Neurol. 2020 Aug;19(8):640-642. (PMID: 32445621)
      N Z Med J. 2007 Jun 29;120(1257):U2607. (PMID: 17632597)
      J Surg Res. 2018 Mar;223:259-260. (PMID: 29198604)
      Clin Interv Aging. 2015 Mar 10;10:549-60. (PMID: 25792818)
      Acta Neuropathol. 2020 Dec;140(6):793-810. (PMID: 32865691)
      N Z Med J. 2006 Jun 02;119(1235):U1997. (PMID: 16751821)
      Diabetes. 2008 May;57(5):1349-54. (PMID: 18299315)
      Diabetes Care. 2016 Feb;39(2):300-7. (PMID: 26681727)
      J Alzheimers Dis. 2020;74(4):1295-1308. (PMID: 32250298)
      JAMA Netw Open. 2022 Feb 1;5(2):e2147171. (PMID: 35129595)
      Cardiovasc Diabetol. 2020 Oct 10;19(1):174. (PMID: 33038936)
      Intern Med J. 2012 May;42(5):484-91. (PMID: 22372522)
      Australas Psychiatry. 2022 Jun;30(3):303-307. (PMID: 34979810)
      Diabetes Res Clin Pract. 2021 May;175:108799. (PMID: 33845053)
      Eur Rev Med Pharmacol Sci. 2014;18(12):1778-89. (PMID: 24992622)
      Psychogeriatrics. 2022 Sep;22(5):666-678. (PMID: 35777977)
      Lancet Neurol. 2020 Sep;19(9):758-766. (PMID: 32730766)
      EClinicalMedicine. 2022 Jul 22;51:101580. (PMID: 35898316)
      Diabetes Obes Metab. 2021 May;23(5):1140-1149. (PMID: 33464682)
      N Z Med J. 2022 Dec 16;135(1567):91-104. (PMID: 36521088)
      Nat Rev Endocrinol. 2018 Oct;14(10):591-604. (PMID: 30022099)
      BMC Endocr Disord. 2019 Aug 22;19(1):87. (PMID: 31438915)
      Ageing Res Rev. 2019 Nov;55:100944. (PMID: 31430566)
      Diabetes Care. 2022 Jan 1;45(1):134-141. (PMID: 34711638)
      BMJ. 2017 Jun 22;357:j2709. (PMID: 28642251)
      N Engl J Med. 2013 Aug 8;369(6):540-8. (PMID: 23924004)
      BMC Endocr Disord. 2020 Mar 12;20(Suppl 1):134. (PMID: 32164656)
      Hypertension. 2020 Jan;75(1):237-245. (PMID: 31735081)
      JAMA. 2006 Apr 12;295(14):1681-7. (PMID: 16609090)
      Diabetologia. 2023 Aug;66(8):1442-1449. (PMID: 37221246)
      Lancet. 2020 Aug 8;396(10248):413-446. (PMID: 32738937)
      Diabetes Care. 2010 Jul;33(7):1674-85. (PMID: 20587728)
      Diabetes Res Clin Pract. 2017 Feb;124:41-47. (PMID: 28088029)
      Diabetes Care. 2018 Jan;41(Suppl 1):S13-S27. (PMID: 29222373)
      Contemp Clin Trials. 2022 Aug;119:106817. (PMID: 35691488)
      Oxid Med Cell Longev. 2015;2015:610813. (PMID: 25834699)
      BJU Int. 2021 Dec;128 Suppl 3:11-17. (PMID: 32599662)
      N Z Med J. 1997 Feb 28;110(1038):48-50. (PMID: 9076284)
      BMJ Open. 2022 Sep 7;12(9):e062304. (PMID: 36691174)
      Alzheimers Dement. 2024 Jul;20(7):4423-4433. (PMID: 38874317)
      N Z Med J. 1999 Sep 24;112(1096):361-3. (PMID: 10587056)
      Nat Rev Neurol. 2018 Mar;14(3):168-181. (PMID: 29377010)
      BMJ Open Diabetes Res Care. 2022 Dec;10(6):. (PMID: 36521879)
      JAMA Psychiatry. 2017 Jul 1;74(7):712-718. (PMID: 28514478)
      JAMA. 2021 Apr 27;325(16):1640-1649. (PMID: 33904867)
    • Contributed Indexing:
      Keywords: dementia; impaired glucose tolerance; landmark analysis; tapered matching; type 2 diabetes
    • Publication Date:
      Date Created: 20240614 Date Completed: 20240715 Latest Revision: 20240717
    • Publication Date:
      20240717
    • Accession Number:
      PMC11247710
    • Accession Number:
      10.1002/alz.13855
    • Accession Number:
      38874317